Bivalirudin
Also referenced as: Angiomax
A hirudin-derived peptide anticoagulant used during coronary procedures.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
FDA-approved as an anticoagulant for PCI, including patients with heparin-induced thrombocytopenia or associated thrombosis under label criteria.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A hirudin-derived peptide anticoagulant used during coronary procedures.
FDA-approved as an anticoagulant for PCI, including patients with heparin-induced thrombocytopenia or associated thrombosis under label criteria.
This is a procedural anticoagulant, not a general heart-health or preventive supplement.
Why It's Being Studied
- PCI anticoagulation
- Thrombin inhibition
Mechanism of Action
Direct thrombin inhibition reduces conversion of fibrinogen to fibrin and thrombin-mediated clot activity.
Direct thrombin inhibition reduces conversion of fibrinogen to fibrin and thrombin-mediated clot activity. This is a procedural anticoagulant, not a general heart-health or preventive supplement.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- PCI anticoagulation
- Thrombin inhibition
- Intravenous approved medicine
Evidence Summary
Clinical evidence supports procedural anticoagulation in percutaneous coronary intervention, including specified HIT/HITTS patients.
Higher tiers carry more weight. Filled tiers have evidence for Bivalirudin; tap to read it.
- Clinical evidence supports procedural anticoagulation in percutaneous coronary intervention, including specified HIT/HITTS patients.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Clinical evidence supports procedural anticoagulation in percutaneous coronary intervention, including specified HIT/HITTS patients.
Reported Adverse Events in Research
- Major bleeding and acute stent thrombosis are important risks.
Limitations of Current Evidence
- This is a procedural anticoagulant, not a general heart-health or preventive supplement.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Bivalirudin | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Bivalirudin — prescribing label